• Jérôme Busserolles, Christoforos Tsantoulas, Alain Eschalier, and José A López García.
• aInserm, U 1107, Neuro-Dol, Clermont-Ferrand, FrancebFundamental and Clinical Pharmacology of Pain, Université Clermont Auvergne, University of Auvergne, Clermont-Ferrand, FrancecWolfson Centre for Age-Related Diseases, King's College London, London, United KingdomdDepartment of pharmacology, CHU Clermont-Ferrand, Clermont-Ferrand, FranceeDepartment of Physiology, University of Alcala, Alcala de Henares, Madrid, Spain.
• Pain. 2016 Feb 1; 157 Suppl 1: S7-14.

AbstractA workshop of the 2015 International Neuropathic Pain Congress was focused on potassium channels to propose emerging ideas on the role of these channels on pain modulation and to determine whether they can become relevant targets for designing novel analgesic compounds. Two kinds of potassium channels were particularly evoked: selected subunits of the voltage-gated potassium (Kv) and of the K2P channel families. In this review, the role of the former is described with a focus first on silent subunits as modulators of Kv and second on the Kv7 subunits. The physiological, pathophysiological, and pharmacological involvement of the K2P in pain modulation is then described. Throughout this review, the role of potassium channels in pain is obvious, which renders them potential targets for innovative analgesics with peripheral and/or central action depending on the channel. Clearly, some preliminary results obtained with known or novel potassium channel openers suggest that they might represent a novel class of analgesics in neuropathic pain or other pathological contexts.

7 keywords...

hide…